Carmot Therapeutics Expands Amgen Deal to Identify Parkinson’s Disease Treatments

Equities Research |

Carmot Therapeutics announced today a new and expanded drug discovery collaboration and licensing program with Amgen (Nasdaq: AMGN) to discover and advance novel drug leads intended for the treatment of Parkinson’s disease and other selected disease areas. Carmot and Amgen will work together to select therapeutic targets and identify drug candidates, while Amgen will be solely responsible for clinical development, manufacturing, and commercialization activities of any resulting molecules. The agreement builds on the strategic collaborative relationship that began in 2014.

Carmot calls its approach Chemotype Evolution, a proprietary technology that dramatically expands the repertoire of chemical diversity for drug discovery according to the company. The approach is iterative, whereby a known target-binding molecule (the bait) is first reacted with a proprietary fragment collection to generate a library of target-directed compounds. This process is sequentially iterated to generate novel candidates from an existing molecule.

Hits identified from a first iteration screen can be fed into a medicinal chemistry program or converted into new baits (Bait B, center left in Figure) and used in a second iteration screen to identify more potent molecules. Alternatively, fragment hits can be repurposed as baits (Bait C) to identify fragments that replace the initial anchor molecule. This process can be repeated multiple times if desired.

Chemotype Evolution

Source: Carmot Therapeutics



Under the terms of the expanded agreement, Amgen can select multiple targets to pursue, and Carmot will receive an upfront payment and research support. Carmot is also eligible to receive milestone payments based on achievement of pre-clinical, clinical, and commercialization milestones potentially worth more than $240 million. In addition, Carmot is eligible to receive royalties on the net sales of products resulting from the collaboration.

Over the past few years, we have greatly expanded the capabilities of Chemotype Evolution to better address unmet chemical needs in drug discovery. Our relationship with Amgen started in 2014 with our first discovery collaboration that was extended in 2016. We are delighted to announce a new and expanded collaboration with Amgen to discover drug candidates for challenging therapeutic targets. Working with Amgen, we will be able to more fully leverage the capabilities of Chemotype Evolution to identify novel drug candidates for the benefit of patients.

- Stig K. Hansen, Carmot’s CEO.

Discovering new medicines to treat debilitating neurodegenerative diseases such as Parkinson’s is a key area of focus for our Neuroscience research team. We’re excited to expand Amgen’s relationship with Carmot to leverage its unique small molecule capabilities to address targets that traditionally have been very difficult to drug.

- John Dunlop, vice president, Neuroscience Research at Amgen.

Please email us at content@equities.com to see our Case Studies and Testimonials.

Please click here for information on our new trading platform.

Please click here to see our weekly newsletter.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
AMGN Amgen Inc. 176.13 -1.25 -0.70 229,893 Trade

Comments

Emerging Growth

Lomiko Metals Inc.

Lomiko Metals Inc is an exploration stage company. It is engaged in the acquisition, exploration and development of resource properties. Its projects include Vines Lake project and Quatre - Milles…

Private Markets

Voleo

Voleo is a free download that allows you to form investment clubs with your friends, family, colleagues, classmates, teammates…basically anyone you know and trust. Invest and manage a stock portfolio…

The Green Organic Dutchman

The Green Organic Dutchman Ltd. ("TGOD") produces farm grown, organic cannabis for medical use. The company grows its high quality organic cannabis in small batches using craft growing, all natural…